Alltrna

As we work together to transform medicine, we never forget the power of teamwork, trust, and collaboration. This November, we dedicated an entire month to gratitude—celebrating our incredible team with meaningful moments of appreciation. From Thankful Thursdays featuring a potluck lunch to Thank You cards where we share personal notes of gratitude, we honored what makes Alltrna so special: our united spirit and relentless commitment to patients. Gratitude isn’t just for one month—it’s a value we carry every day. #GratitudeMonth #TeamAlltrna #WeAreAlltrna #Gratitude

We are looking forward to the Piper Sandler 36th Annual Healthcare Conference taking place December 3-5 in New York City. Our CEO Michelle Werner will be presenting on how we are leveraging Alltrna’s platform, enabled by AI and machine learning, to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. Learn more: www.alltrna.com #tRNAmedicines #tRNA #rarediseases #raredisease #StopCodonDisease? #geneticmedicines #AI #machinelearning

As leaders in translating tRNA biology into transformative medicines, we're proud to sponsor and present at the ???????? ???????? ???????????????????? in Kanazawa, Japan, from November 18-22. Since 1969, this biennial gathering has brought together experts to explore cutting-edge advancements in tRNA biology. We look forward to sharing Alltrna’s innovative approach in designing and delivering tRNA as a groundbreaking therapeutic modality. We will have a seminar and a poster where we will present proof-of-concept data on the ability of our engineered tRNAs to readthrough premature termination codons and restore protein production.? We are excited about what these data mean for the potential creation of universal medicines to treat diseases that share these genetic mutations, collectively referred to as Stop Codon Disease. To see more about the conference, visit: https://lnkd.in/gYRzmtHy #tRNAmedicines #tRNA #rarediseases #raredisease #StopCodonDisease? #geneticmedicines #AI #machinelearning

Our CEO Michelle Werner will be participating in Jefferies London Healthcare Conference 2024, and sharing how Alltrna is advancing universal tRNA medicines to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.? https://www.alltrna.com/ #JefferiesHealthcare #tRNAmedicines? #tRNA #rarediseases #raredisease #StopCodonDisease? #geneticmedicines

We are thrilled to welcome Sandra Visser, Ph.D., to the Alltrna team as SVP, Head of Therapeutics Development! With over two decades of experience in quantitative medicine, drug discovery, and strategic development, Sandra is driven by a passion for accelerating novel therapies and improving patient outcomes. Her impressive background includes leadership roles at GSK, Merck, and AstraZeneca, where she and her teams made groundbreaking advancements in preclinical and clinical drug projects. Join us in welcoming Sandra to Alltrna! #tRNAmedicines? #tRNA #rarediseases #raredisease #StopCodonDisease? #geneticmedicines

?? Spooky season fun with the Alltrna team! ?? Today, we celebrated Halloween in style with a festive brunch filled with costumes, laughs, and delicious treats. From mad scientists to monsters, our team got into the Halloween spirit—proving that we can be serious about #tRNA research and have a frighteningly good time. Happy Halloween from #TeamAlltrna! ????

Did you know that chemical modifications on tRNAs play a key role in their structure, function, and stability? Chemically modified tRNAs have not previously been produced successfully at a scale required for preclinical development and clinical trials. To advance our first tRNA medicines to the clinic, Alltrna has pioneered the chemical synthesis of modified tRNA oligonucleotides. Alltrna’s Chief Technology Officer William Kiesman explains about manufacturing tRNAs and more in this BioProcess International interview: https://lnkd.in/dmKfkQDX #tRNA #RNA #tRNAmedicines #manufacturing #rarediseases #geneticmedicines

Thank you to Tom DiLenge and all the speakers for driving crucial conversations that inspire change. At Alltrna, we are committed to transforming medicine, boldly building a new future for patients and accelerating drug development for rare diseases. #tRNAmedicines? #tRNA #rarediseases #raredisease #StopCodonDisease? #geneticmedicines

How can we accelerate drug development and balance risk when a patient’s time is short? Alltrna CEO Michelle Werner was one of three parents who took the stage at the #STATSummit to discuss building biotech companies and changing drug development paradigms in a race against time to bring new treatments for #rarediseases that affect their children. Read the STAT story: https://lnkd.in/gt99m5ND

Not all RNAs are created equal. tRNAs have some incredible therapeutic potential, but also unique challenges in terms of sequencing and chemical synthesis. In this Q&A with Drug Discovery World, Caroline K?hrer, Alltrna's Senior Vice President of Discovery Platform, breaks down the biology and how Alltrna is harnessing it to create tRNA therapeutics that can unify the treatment of diseases based on shared genetic mutations and accelerate rare disease drug development for millions. Read the article here: https://lnkd.in/egAY6_nC #RNA #tRNAmedicines #tRNAbiology #rarediseases #geneticmedicines #programmablemedicines #AI #machinelearning #StopCodonDisease